BMO Capital Cuts Price target on Valeant Pharma (VRX) Following Poor 3Q Legacy Business Performance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to BMO Capital Cuts Price target on Valeant Pharma (VRX) Following Poor 3Q Legacy Business Performance

Valeant Pharmaceuticals Reports Third Quarter 2015 Financial Results

October 19, 2015 6:00 AM EDT

LAVAL, Quebec, Oct. 19, 2015 /PRNewswire/ --

2015 Third Quarter Results

Total Revenues of $2.8 billion; an increase of 36% over the prior year despite negative foreign exchange impact of $172 million Same store sales organic growth of 13%; 5th consecutive quarter of > 10% organic growth, driven by: Continued outperformance of U.S. businesses, particularly dermatology and contact lens Strong results in China (23%), South Korea (15%) and Mexico (10%) Total company growth was 8.2% volume and 4.4% price U.S. branded pharmaceuticals growth was 18.8% volume... More